Stock analysis, trade plans, and proprietary indicators by Trend Edge.
Trend Edge Setup Score
Trend Edge rates SLS Bullish with a Setup Score of 0, net conviction 49, actionability 0. How the Setup Score works →
Total Setup Score
0
Directional Bias
Bullish
Net Conviction
49
Actionability
0 (extended)
Key signals behind this score
40wk Uptrend — rising+above (sma 4.91 vs px 12.76)
80wk Uptrend — rising+above (sma 3.21 vs px 12.76)
200wk Uptrend — rising+above (sma 2.24 vs px 12.76)
Funds Accumulating — momZ +10.28 · 1.34→1.80
Founder-Led — founder/CEO led
About Sellas Life Sciences Group Inc
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. Read full Trend Edge analysis →
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
IPO Date: December 29, 2017
Headquarters: 7 Times Square, New York, NY, United States, 10036
Founder-Led: Yes — Angelos Stergiou (Founder, President, CEO & Director)
Key Metrics
Current Price
$12.76
Market Cap
$2.66B
Float
185.2M
Shares Outstanding
196.6M
Price/Sales (TTM)
26.90
vs. Analyst Target
+37.1% to analyst PT
Dividend Rate
None
Analyst Target Price
$17.50 (3 analysts)
Financial History
Annual Revenue & Earnings History
Year
Revenue
Net Income
Gross Profit
EBITDA
2020
$1,900
-$16.8M
$1,900
$26.5M
2021
$7.6M
-$20.7M
$7.4M
-$18.3M
2022
$1.0M
-$41.3M
$900,000
-$31.5M
2023
N/A
-$37.3M
N/A
$529,000
2024
N/A
-$30.9M
N/A
$632,000
2025
N/A
-$26.9M
N/A
-$26.9M
Recent Quarterly Revenue & Net Income
Quarter
Revenue
Net Income
Jun 2025
N/A
-$6.6M
Sep 2025
N/A
-$6.8M
Dec 2025
N/A
-$7.7M
Mar 2026
N/A
-$8.4M
Ownership & Float
Insider Ownership
0.9%
Institutional Ownership
27.8%
Short Float
34.2%
% of All Funds Holding
1.80%
Number of Funds Holding
148
Current Moving Averages
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
Timeframe
SMA
Value
Trend Context
Weekly
10-Week SMA
$9.34
Near-term / short-term trend
Weekly
40-Week SMA
$4.90
Medium-term trend
Weekly
80-Week SMA
$3.21
Cyclical trend (business cycle)
Weekly
200-Week SMA
$2.24
Secular trend (multi-year)
Monthly
10-Month SMA
$6.19
Near-term monthly trend
Monthly
20-Month SMA
$3.87
Medium-term monthly trend
Monthly
40-Month SMA
$2.56
Secular monthly trend
Volume Shelves — Support & Resistance
Trend Edge identifies volume shelves: price zones where historically elevated trading volume
creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative
volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Price Level
Type
Volume Ratio
Age
$9.10
support
1.45x
0 months ago
$5.00
support
1.67x
1 months ago
$3.70
support
1.13x
4 months ago
$1.60
support
2.74x
6 months ago
$1.10
support
1.08x
14 months ago
Historical Earnings Reactions (72 events)
Timeframe
Avg Return
Median
Win Rate
Best
Worst
Gap
-1.14%
0.00%
44.44%
21.07%
-52.57%
1 Day
-2.63%
-1.10%
31.94%
25.10%
-53.66%
1 Week
-1.86%
-3.88%
34.72%
71.84%
-56.91%
2 Weeks
1.95%
-2.43%
43.06%
77.98%
-62.87%
1 Month
1.75%
-2.70%
43.66%
169.96%
-82.35%
Next earnings: August 11, 2026 (30 days away)
Seasonality & Day-of-Week Patterns
Monthly Seasonality
Month
Avg Return
Win Rate
Samples
Jan
-0.6%
50.0%
18
Feb
0.7%
44.4%
18
Mar
0.1%
33.3%
18
Apr
1.7%
36.8%
19
May
15.9%
68.4%
19
Jun
-10.9%
31.6%
19
Jul
-4.0%
33.3%
18
Aug
-6.9%
33.3%
18
Sep
1.1%
38.9%
18
Oct
3.7%
38.9%
18
Nov
-1.5%
33.3%
18
Dec
5.1%
27.8%
18
Day-of-Week Tendencies
Day
Avg Return
Win Rate
Samples
Monday
0.14%
41.8%
865
Tuesday
0.05%
43.2%
948
Wednesday
-0.03%
41.7%
945
Thursday
0.22%
41.5%
927
Friday
-0.18%
43.6%
921
Top Institutional Holders
Institutional holder breakdown coming soon.
Total institutional ownership: 27.8%
Insider Transactions — Smart Summary
Total insider ownership: 0.9%
Founder-led management: Angelos Stergiou (Founder, President, CEO & Director)
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Sellas Life Sciences Group Inc
(SLS) powered by Claude Opus — Anthropic's most capable AI model.
The analysis covers five layers:
technical analysis (near-term, medium-term, cyclical, and secular trend, momentum,
volume shelf support and resistance, breakout and breakdown signals),
qualitative analysis (business model, competitive moat, sector dynamics),
insider sentiment (buy and sell signals from executive and director transactions),
share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and
fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit,
stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward.
Whether you are building a long position, initiating a short, or looking for a reversal setup,
AI Consult identifies the highest-probability signal from the current trend.